Top

Published in:

01-06-2018 | Review Article

An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)

Authors: Maliha Khan, Rabbia Siddiqi, Kiran Naqvi

Published in: Annals of Hematology | Issue 6/2018

Abstract

Mixed phenotype acute leukemia (MPAL) is an uncommon diagnosis, representing only about 2–5% of acute leukemia cases. The blast cells of MPAL express multilineage immunophenotypic markers and may have a shared B/T/myeloid phenotype. Due to historical ambiguity in the diagnosis of MPAL, the genetics and clinical features of this disease remain poorly characterized. Based on the 2008 and 2016 World Health Organization classifications, myeloid lineage is best determined by presence of myeloperoxidase, while B and T lymphoid lineages are demonstrated by CD19 and cytoplasmic CD3 expression. MPAL typically carries a worse prognosis than either acute myeloid leukemia (AML) or acute lymphoid leukemia (ALL). Given the rarity of MPAL, there is a lack of prospective trial data to guide therapy; treatment generally relies on ALL-like regimens followed by consolidation chemotherapy or hematopoietic stem cell transplant (HSCT). Here, we review the updated classification, biology, clinical features, and treatment approach to MPAL.

Weinberg OK, Arber DA (2010) Mixed-phenotype acute leukemia: historical overview and a new definition. Leukemia 24(11):1844–1851. https://doi.org/10.1038/leu.2010.202 CrossRefPubMed

Altman AJ (1990) Clinical features and biological implications of acute mixed lineage (hybrid) leukemias. Am J Pediatr Hematol Oncol 12(2):123–133CrossRefPubMed

Mirro J, Zipf TF, Pui CH, Kitchingman G, Williams D, Melvin S, Murphy SB, Stass S (1985) Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance. Blood 66(5):1115–1123PubMed

Sulak LE, Clare CN, Morale BA, Hansen KL, Montiel MM (1990) Biphenotypic acute leukemia in adults. Am J Clin Pathol 94(1):54–58CrossRefPubMed

Catovsky D, Matutes E, Buccheri V, Shetty V, Hanslip J, Yoshida N, Morilla R (1991) A classification of acute leukaemia for the 1990s. Ann Hematol 62(1):16–21CrossRefPubMed

Bene MC, Bernier M, Casasnovas RO, Castoldi G, Knapp W, Lanza F, Ludwig WD, Matutes E, Orfao A, Sperling C, van’t Veer MB (1998) The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 92(2):596–599PubMed

Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 9(10):1783–1786PubMed

Jaffe E, Harris N, Stein HVJ, Vardiman JW (2001) Pathology and genetics of tumors of hematopoietic and lymphoid tissues, 2nd printing, World Health Organization classification of Tumours. IARC Press, Lyon, France

Borowitz MJ, Bene MC, Harris NL, Porwit A, Matutes E (2008) Acute leukemias of ambiguous lineage. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France

10.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544 CrossRefPubMed

11.

Shi R, Munker R (2015) Survival of patients with mixed phenotype acute leukemias: a large population-based study. Leuk Res 39(6):606–616. https://doi.org/10.1016/j.leukres.2015.03.012 CrossRefPubMed

12.

van den Ancker W, Terwijn M, Westers TM, Merle PA, van Beckhoven E, Drager AM, Ossenkoppele GJ, van de Loosdrecht AA (2010) Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification. Leukemia 24(7):1392–1396. https://doi.org/10.1038/leu.2010.119 CrossRefPubMed

13.

Yan L, Ping N, Zhu M, Sun A, Xue Y, Ruan C, Drexler HG, Macleod RA, Wu D, Chen S (2012) Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica 97(11):1708–1712. https://doi.org/10.3324/haematol.2012.064485 CrossRefPubMedPubMedCentral

14.

Pawar RN, Banerjee S, Bramha S, Krishnan S, Bhattacharya A, Saha V, Chakrapani A, Bhave S, Chandy M, Nair R, Parihar M, Arora N, Mishra DK (2017) Mixed-phenotypic acute leukemia series from tertiary care center. Indian J Pathol Microbiol 60(1):43–49. https://doi.org/10.4103/0377-4929.200057 PubMed

15.

Matutes E, Pickl WF, Van't Veer M, Morilla R, Swansbury J, Strobl H, Attarbaschi A, Hopfinger G, Ashley S, Bene MC, Porwit A, Orfao A, Lemez P, Schabath R, Ludwig WD (2011) Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood 117(11):3163–3171. https://doi.org/10.1182/blood-2010-10-314682 CrossRefPubMed

16.

Orkin SH, Zon LI (2008) Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132(4):631–644. https://doi.org/10.1016/j.cell.2008.01.025 CrossRefPubMedPubMedCentral

17.

Regalo G, Leutz A (2013) Hacking cell differentiation: transcriptional rerouting in reprogramming, lineage infidelity and metaplasia. EMBO Mol Med 5(8):1154–1164. https://doi.org/10.1002/emmm.201302834 CrossRefPubMedPubMedCentral

18.

Simmons S, Knoll M, Drewell C, Wolf I, Mollenkopf HJ, Bouquet C, Melchers F (2012) Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development. Blood 120(18):3688–3698. https://doi.org/10.1182/blood-2012-03-414821 CrossRefPubMed

19.

Hsu CL, King-Fleischman AG, Lai AY, Matsumoto Y, Weissman IL, Kondo M (2006) Antagonistic effect of CCAAT enhancer-binding protein-alpha and Pax5 in myeloid or lymphoid lineage choice in common lymphoid progenitors. Proc Natl Acad Sci U S A 103(3):672–677. https://doi.org/10.1073/pnas.0510304103 CrossRefPubMedPubMedCentral

20.

De Obaldia ME, Bell JJ, Wang X, Harly C, Yashiro-Ohtani Y, DeLong JH, Zlotoff DA, Sultana DA, Pear WS, Bhandoola A (2013) T cell development requires constraint of the myeloid regulator C/EBP-alpha by the Notch target and transcriptional repressor Hes1. Nat Immunol 14(12):1277–1284. https://doi.org/10.1038/ni.2760 CrossRefPubMedPubMedCentral

21.

Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Lowenberg B, Dohner H, Dohner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE (2016) Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med 22(7):792–799. https://doi.org/10.1038/nm.4125 CrossRefPubMedPubMedCentral

22.

Heesch S, Neumann M, Schwartz S, Bartram I, Schlee C, Burmeister T, Hanel M, Ganser A, Heuser M, Wendtner CM, Berdel WE, Gokbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD (2013) Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Ann Hematol 92(6):747–758. https://doi.org/10.1007/s00277-013-1694-4 CrossRefPubMed

23.

Al-Seraihy AS, Owaidah TM, Ayas M, El-Solh H, Al-Mahr M, Al-Ahmari A, Belgaumi AF (2009) Clinical characteristics and outcome of children with biphenotypic acute leukemia. Haematologica 94(12):1682–1690. https://doi.org/10.3324/haematol.2009.009282 CrossRefPubMedPubMedCentral

24.

Park JA, Ghim TT, Bae K, Im HJ, Jang SS, Park CJ, Chi HS, Seo JJ (2009) Stem cell transplant in the treatment of childhood biphenotypic acute leukemia. Pediatr Blood Cancer 53(3):444–452. https://doi.org/10.1002/pbc.22105 CrossRefPubMed

25.

Owaidah TM, Al Beihany A, Iqbal MA, Elkum N, Roberts GT (2006) Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia 20(4):620–626. https://doi.org/10.1038/sj.leu.2404128 CrossRefPubMed

26.

Rubnitz JE, Onciu M, Pounds S, Shurtleff S, Cao X, Raimondi SC, Behm FG, Campana D, Razzouk BI, Ribeiro RC, Downing JR, Pui CH (2009) Acute mixed lineage leukemia in children: the experience of St Jude Children’s Research Hospital. Blood 113(21):5083–5089. https://doi.org/10.1182/blood-2008-10-187351 CrossRefPubMedPubMedCentral

27.

Manola KN (2013) Cytogenetic abnormalities in acute leukaemia of ambiguous lineage: an overview. Br J Haematol 163(1):24–39. https://doi.org/10.1111/bjh.12484 CrossRefPubMed

28.

Hoehn D, Medeiros LJ, Chen SS, Tian T, Jorgensen JL, Ahmed Y, Lin P (2012) CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol 137(2):213–219. https://doi.org/10.1309/AJCPR3N3JMSYLPFG CrossRefPubMed

29.

Kern W, Grossmann V, Roller A, Weissmann S, Alpermann T, Schoeck U, Haferlach C, Schnittger S, Haferlach T, Kohlmann A (2012) Mixed phenotype acute leukemia, T/myeloid, NOS (MPAL-TM) has a high <em>DNMT3A</em> mutation frequency and carries further genetic features of both AML and T-ALL: results of a comprehensive next-generation sequencing study analyzing 32 genes. Blood 120(21):403–403

30.

Kotrova M, Musilova A, Stuchly J, Fiser K, Starkova J, Mejstrikova E, Stary J, Zuna J, Hrusak O, Trka J, Zaliova M (2016) Distinct bilineal leukemia immunophenotypes are not genetically determined. Blood 128(18):2263–2266. https://doi.org/10.1182/blood-2016-07-725861 CrossRefPubMed

31.

Eckstein OS, Wang L, Punia JN, Kornblau SM, Andreeff M, Wheeler DA, Goodell MA, Rau RE (2016) Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes. Exp Hematol 44(8):740–744. https://doi.org/10.1016/j.exphem.2016.05.003 CrossRefPubMedPubMedCentral

32.

Neumann M, Heesch S, Schlee C, Schwartz S, Gokbuget N, Hoelzer D, Konstandin NP, Ksienzyk B, Vosberg S, Graf A, Krebs S, Blum H, Raff T, Bruggemann M, Hofmann WK, Hecht J, Bohlander SK, Greif PA, Baldus CD (2013) Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood 121(23):4749–4752. https://doi.org/10.1182/blood-2012-11-465138 CrossRefPubMed

33.

Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481(7380):157–163. https://doi.org/10.1038/nature10725 CrossRefPubMedPubMedCentral

34.

Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D (2009) Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 10(2):147–156. https://doi.org/10.1016/S1470-2045(08)70314-0 CrossRefPubMedPubMedCentral

35.

Weir EG, Ali Ansari-Lari M, Batista DA, Griffin CA, Fuller S, Smith BD, Borowitz MJ (2007) Acute bilineal leukemia: a rare disease with poor outcome. Leukemia 21(11):2264–2270. https://doi.org/10.1038/sj.leu.2404848 CrossRefPubMed

36.

Killick S, Matutes E, Powles RL, Hamblin M, Swansbury J, Treleaven JG, Zomas A, Atra A, Catovsky D (1999) Outcome of biphenotypic acute leukemia. Haematologica 84(8):699–706PubMed

37.

Xu XQ, Wang JM, Lu SQ, Chen L, Yang JM, Zhang WP, Song XM, Hou J, Ni X, Qiu HY (2009) Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. Haematologica 94(7):919–927. https://doi.org/10.3324/haematol.2008.003202 CrossRefPubMedPubMedCentral

38.

Legrand O, Perrot JY, Simonin G, Baudard M, Cadiou M, Blanc C, Ramond S, Viguie F, Marie JP, Zittoun R (1998) Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression. Br J Haematol 100(1):147–155CrossRefPubMed

39.

Lee JH, Min YH, Chung CW, Kim BK, Yoon HJ, Jo DY, Shin HJ, Bang SM, Won JH, Zang DY, Kim HJ, Chi HS, Lee KH, Cheong JW, Kim JS, Kim SH, Park S, Park SY, Chung JS, Lee JH, Park CJ, Korean Society of Hematology AMLMDSWP (2008) Prognostic implications of the immunophenotype in biphenotypic acute leukemia. Leuk Lymphoma 49(4):700–709. https://doi.org/10.1080/10428190701843247 CrossRefPubMed

40.

Zhang Y, Wu D, Sun A, Qiu H, He G, Jin Z, Tang X, Miao M, Fu Z, Han Y (2011) Clinical characteristics, biological profile, and outcome of biphenotypic acute leukemia: a case series. Acta Haematol 125(4):210–218. https://doi.org/10.1159/000322594 CrossRefPubMed

41.

Deffis-Court M, Alvarado-Ibarra M, Ruiz-Arguelles GJ, Rosas-Lopez A, Barrera-Lumbreras G, Aguayo-Gonzalez A, Lopez-Karpovitch X, Lopez-Hernandez M, Velazquez-Sanchez de Cima S, Zamora-Ortiz G, Crespo-Solis E (2014) Diagnosing and treating mixed phenotype acute leukemia: a multicenter 10-year experience in Mexico. Ann Hematol 93(4):595–601. https://doi.org/10.1007/s00277-013-1919-6 CrossRefPubMed

42.

Zheng C, Wu J, Liu X, Ding K, Cai X, Zhu W (2009) What is the optimal treatment for biphenotypic acute leukemia? Haematologica 94(12):1778–1780; author reply 1780. https://doi.org/10.3324/haematol.2009.014829 CrossRefPubMedPubMedCentral

43.

Weinberg OK, Seetharam M, Ren L, Alizadeh A, Arber DA (2014) Mixed phenotype acute leukemia: a study of 61 cases using World Health Organization and European Group for the immunological classification of leukaemias criteria. Am J Clin Pathol 142(6):803–808. https://doi.org/10.1309/AJCPPVUPOTUVOIB5 CrossRefPubMed

44.

Wolach O, Stone RM (2015) How I treat mixed-phenotype acute leukemia. Blood 125(16):2477–2485. https://doi.org/10.1182/blood-2014-10-551465 CrossRefPubMed

45.

Porwit A, Bene MC (2015) Acute leukemias of ambiguous origin. Am J Clin Pathol 144(3):361–376. https://doi.org/10.1309/AJCPSTU55DRQEGTE CrossRefPubMed

46.

Pomerantz A, Rodriguez-Rodriguez S, Demichelis-Gomez R, Barrera-Lumbreras G, Barrales-Benitez O, Lopez-Karpovitch X, Aguayo-Gonzalez A (2016) Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used. Blood Res 51(4):233–241. https://doi.org/10.5045/br.2016.51.4.233 CrossRefPubMedPubMedCentral

47.

Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F (2007) Biphenotypic acute leukaemia: a case series. Br J Haematol 138(2):213–216. https://doi.org/10.1111/j.1365-2141.2007.06634.x CrossRefPubMed

48.

Lee JY, Lee SM, Lee JY, Kim KH, Choi MY, Lee WS (2016) Mixed-phenotype acute leukemia treated with decitabine. Korean J Intern Med 31(2):406–408. https://doi.org/10.3904/kjim.2014.353 CrossRefPubMedPubMedCentral

49.

Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X, Han Y, Fu Z, Qiu H, Sun A, Wu D (2016) Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. Leuk Res 45:40–46. https://doi.org/10.1016/j.leukres.2016.04.002 CrossRefPubMed

50.

Shimizu H, Saitoh T, Machida S, Kako S, Doki N, Mori T, Sakura T, Kanda Y, Kanamori H, Miyawaki S, Okamoto S, Kanto Study Group for Cell T (2015) Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol 95(5):455–460. https://doi.org/10.1111/ejh.12516 CrossRefPubMed

51.

Munker R, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W, Center for International B, Marrow Transplant R (2016) Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia. Biol Blood Marrow Transplant 22(6):1024–1029. https://doi.org/10.1016/j.bbmt.2016.02.013 CrossRefPubMedPubMedCentral

52.

Liu QF, Fan ZP, Wu MQ, Sun J, Wu XL, Xu D, Jiang QL, Zhang Y, Huang F, Wei YQ, Zhao J, Yu GP, Meng FY (2013) Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens. Ann Hematol 92(5):679–687. https://doi.org/10.1007/s00277-012-1662-4 CrossRefPubMed

53.

Wolach O, Stone RM (2017) Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Curr Opin Hematol 24(2):139–145. https://doi.org/10.1097/MOH.0000000000000322 CrossRefPubMed

54.

DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM (2015) Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia 29(3):526–534. https://doi.org/10.1038/leu.2014.229 CrossRefPubMed

55.

Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, Duggan D, Davey FR, Sobol RE, Frankel SR et al (1995) A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 85(8):2025–2037PubMed

56.

Shimizu H, Yokohama A, Hatsumi N, Takada S, Handa H, Sakura T, Nojima Y (2014) Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol 93(4):297–301. https://doi.org/10.1111/ejh.12343 CrossRefPubMed

57.

Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, Waters NJ, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM (2013) Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122(6):1017–1025. https://doi.org/10.1182/blood-2013-04-497644 CrossRefPubMedPubMedCentral

58.

Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM, Pollock RM (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20(1):53–65. https://doi.org/10.1016/j.ccr.2011.06.009 CrossRefPubMedPubMedCentral

59.

Fung TK, Gandillet A, So CW (2012) Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/beta-catenin pathway. Curr Opin Hematol 19(4):280–286. https://doi.org/10.1097/MOH.0b013e3283545615 CrossRefPubMed

60.

Zhao XF, Gojo I, York T, Ning Y, Baer MR (2009) Diagnosis of biphenotypic acute leukemia: a paradigmatic approach. Int J Clin Exp Pathol 3(1):75–86PubMed

61.

Carbonell F, Swansbury J, Min T, Matutes E, Farahat N, Buccheri V, Morilla R, Secker-Walker L, Catovsky D (1996) Cytogenetic findings in acute biphenotypic leukaemia. Leukemia 10(8):1283–1287PubMed

62.

Buccheri V, Matutes E, Dyer MJ, Catovsky D (1993) Lineage commitment in biphenotypic acute leukemia. Leukemia 7(6):919–927PubMed

Title: An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)
Authors: Maliha Khan
Rabbia Siddiqi
Kiran Naqvi
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 6/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3297-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review

Progressive transformation of germinal centers: an illustration of two clinical cases

Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation

Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients

Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma

Molecular characteristic of acute leukemias with t(16;21)/FUS-ERG

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials